Community Intervention to Reduce Tobacco Use in Pregnant Women

Nicotine Dependence Clinical Trial

— Sisters  

Official title:

Community Intervention to Reduce Tobacco Use Among Alaska Native Pregnant Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02083081
• Other study ID #: 13-008824
• Secondary ID: 1R01CA164533
• Status: Completed
• Phase: N/A
• Start date: May 2014
• Est. completion date: December 2020

Study information

• Verified date: June 2022
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the southwest region of Alaska where the project takes place, 79% of Alaska Native women smoke cigarettes or use smokeless tobacco (ST) during pregnancy. In addition, pregnancy appears to be a high risk period for initiation of tobacco use, primarily ST, among women reporting no use of tobacco 3 months before pregnancy. Intervention efforts targeting the entire community, not only pregnant women, to address social norms about tobacco use may be effective. Thus, the investigators will evaluate the efficacy of a novel, multi-component, theory-based intervention for reducing tobacco use during pregnancy, incorporating both individually targeted and community level components delivered by female elders "Native Sisters." The intervention builds on effective community and individual-based approaches for tobacco cessation and lay health advisor approaches for cancer prevention among Native American women. As part of the intervention, a social marketing campaign including digital stories and other small media will be developed with community feedback. Individually targeted components will be six 30-40 minute telephone or home-based peer counseling sessions with pregnant women.

Description:

The project will be conducted in two phases. In Phase I, the investigators will develop the social marketing components by obtaining qualitative feedback from pregnant women, family members and elders on message content and delivery channels. In Phase II, the investigators will evaluate the intervention using a group-randomized design with village as the unit of assignment. Sixteen villages will be randomly assigned to receive the intervention or control condition (usual care), with > 20 pregnant women enrolled from each village. Assessments will be completed by enrolled women through 6 months postpartum. All aspects of the project will be guided by a Community Advisory Committee. The Specific Aims are: Aim 1. To develop and pre-test the social marketing campaign messages and delivery channels through focus groups and individual interviews of pregnant women, family members, and elders. The focus group work will assess reasons for initiating or continuing tobacco use during pregnancy and the potential role of other community members in addressing tobacco use in pregnancy. Findings will be used to develop campaign messages and media that will be pre-tested through individual interviews and refined. Session content for the individually targeted intervention components will also be developed to align with the campaign messages. Aim 2. To evaluate the efficacy of the intervention compared with the control condition on the biochemically confirmed 7-day point prevalence tobacco use rate at week 36 gestation and at 6 months postpartum. Hypothesis: Compared with the control condition, the intervention will be associated with significantly lower rates of tobacco use in late pregnancy (80% vs. 65%) and at 6 months postpartum (70% vs. 55%). Aim 3. To examine the effect of the intervention on proposed social cognitive-theory based mediators of change including perceived social norms about tobacco use and self-efficacy for non-tobacco use. Hypothesis: Intervention effects on tobacco use at week 36 gestation and at 6 months postpartum will be mediated by perceived self-efficacy and anti-tobacco norms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 352
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Alaska Native
• >18 years of age
• able to provide written informed consent
• currently pregnant and at < 26 weeks gestation
• has access to a working telephone.

Exclusion Criteria:

• plans to have an abortion

Related Conditions & MeSH terms

• Nicotine Dependence
• Tobacco Use Disorder

Intervention

Behavioral:
• Community level intervention
Community intervention plus individual counseling

Locations

Country	Name	City	State
United States	Yukon Kuskokwim Health Corporation	Bethel	Alaska

Sponsors (4)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI), University of Minnesota, Yukon Kuskokwim Health Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Tobacco Abstinence at 6-months Post-partum	Total number of participants to have biochemically confirmed tobacco abstinence at 6-months post-partum	6 months postpartum
Primary	Number of Participants With Tobacco Abstinence at End of Pregnancy	Total number of participants to have biochemically confirmed tobacco abstinence at end of pregnancy (delivery).	Approximately 9 months
Secondary	Change in Self-efficacy for Non-tobacco Use Scores	Change from baseline in self-efficacy for non-tobacco use scores measured by the self-reported Smoking Confidence Questionnaire. Total scores range from 0-30, higher scores indicate better outcome.	Baseline, 6 months postpartum

External Links

•   Mayo Clinic Clinical Trials